0001209191-17-056991.txt : 20171016 0001209191-17-056991.hdr.sgml : 20171016 20171016152433 ACCESSION NUMBER: 0001209191-17-056991 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171016 FILED AS OF DATE: 20171016 DATE AS OF CHANGE: 20171016 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SLATTERY JOSEPH P CENTRAL INDEX KEY: 0001246530 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19437 FILM NUMBER: 171138620 MAIL ADDRESS: STREET 1: C/O SAFESTITCH MEDICAL, INC. STREET 2: 635 DAVID DRIVE, SUITE 300 CITY: MORRISVILLE STATE: NC ZIP: 27560 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TRANSENTERIX INC. CENTRAL INDEX KEY: 0000876378 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 112962080 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 635 DAVIS DRIVE STREET 2: SUITE 300 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919-765-8400 MAIL ADDRESS: STREET 1: 635 DAVIS DRIVE STREET 2: SUITE 300 CITY: MORRISVILLE STATE: NC ZIP: 27560 FORMER COMPANY: FORMER CONFORMED NAME: SafeStitch Medical, Inc. DATE OF NAME CHANGE: 20080211 FORMER COMPANY: FORMER CONFORMED NAME: CELLULAR TECHNICAL SERVICES CO INC DATE OF NAME CHANGE: 19930328 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-10-16 0 0000876378 TRANSENTERIX INC. TRXC 0001246530 SLATTERY JOSEPH P C/O TRANSENTERIX, INC. 635 DAVIS DRIVE, SUITE 300 MORRISVILLE NC 27560 0 1 0 0 EVP and CFO Common Stock 2017-10-16 4 X 0 200000 1.00 A 644365 D Common Stock 25000 I By IRA Series A Warrants 1.00 2017-10-16 4 X 0 200000 0.00 D 2017-05-03 2017-10-31 Common Stock 200000 0 D On October 16, 2017, the reporting person exercised his Series A warrants to purchase 200,000 shares of common stock of TransEnterix, Inc. (the "Company"), par value $0.001 per share, for a purchase price of $1.00 per share. The expiration date of the Series A warrant accelerated to the date that is 10 business days after the Company provides written notice to warrant holders of its receipt of FDA clearance for the Senhance System, as set forth in the warrant. /s/ Joshua Weingard as attorney-in-fact for Joseph Slattery 2017-10-16